Ubs Oconnor LLC Seagen Inc. Transaction History

Ubs Oconnor LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$0.0 - $228.9 $0 - $401 Million	-1,750,496 Closed	0 $0
Q3 2023 Feb 14, 2024	SELL	$191.51 - $216.16 $18.9 Million - $21.3 Million	-98,609 Reduced 5.33%	1,750,496 $371 Billion
Q2 2023 Feb 14, 2024	BUY	$187.64 - $206.25 $239 Million - $263 Million	1,274,105 Added 221.58%	1,849,105 $356 Billion
Q1 2023 Feb 14, 2024	BUY	$127.59 - $203.08 $73.4 Million - $117 Million	575,000 New	575,000 $116 Billion
Q1 2023 May 15, 2023	SELL	$127.59 - $203.08 $272,021 - $432,966	-2,132 Reduced 59.87%	1,429 $289,000
Q4 2022 Feb 14, 2023	SELL	$117.37 - $139.17 $168,895 - $200,265	-1,439 Reduced 28.78%	3,561 $0
Q3 2022 Nov 14, 2022	BUY	$135.27 - $180.11 $676,350 - $900,550	5,000 New	5,000 $684 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

Stay updated on Ubs Oconnor LLC with notifications on news.